Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for fabry patients: long-term drug shows safety promise

NCT ID NCT04049760

First seen Feb 05, 2026 · Last updated May 01, 2026 · Updated 16 times

Summary

This study looked at the long-term safety of a drug called migalastat in 16 people over age 12 with Fabry disease who have certain genetic changes. Fabry disease is a rare inherited condition that can cause pain, organ damage, and other serious problems. The goal was to see if taking migalastat over time is safe and how it affects kidney function and protein levels in urine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229, United States

  • Lysosomal & Rare Disorders Research & Treatment Center

    Fairfax, Virginia, 22030, United States

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • The Emory Clinic

    Atlanta, Georgia, 30322, United States

  • University of Minnesota Masonic Children's Hospital and Clinics

    Minneapolis, Minnesota, 55454, United States

  • University of South Florida

    Tampa, Florida, 33606, United States

Conditions

Explore the condition pages connected to this study.